Aspirin Use for Secondary Prevention Amid Negative Messaging in Patients With Cardiovascular Disease

This cross-sectional study assesses whether aspirin use for secondary prevention changed from 2015 to 2020 and investigates the factors associated with stopping therapy among adults with atherosclerotic cardiovascular disease.

Corresponding Author: Jeremy R. Van’t Hof, MD, MS, Cardiovascular Division and Lillehei Heart Institute, University of Minnesota Medical School, 420 Delaware St SE, MMC 508, Minneapolis, MN 55455 (vanth008@umn.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.